NewAmsterdam Pharma Company N.V. Ordinary Shares NAMS
i
Market dataready · fetched 2026-11-14T02:11:16.295Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T21:00:00.673392731Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-14T02:11:15.447201+00:00
NewAmsterdam Pharma Company N.V. Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 14.67 | 415.4% | 35.6% | |||
| 25Δ | 17.62 | 173.8% | 16.5% | |||
| 30Δ | 22.73 | 99.7% | 15.5% | 18.22 | 160.7% | 14.0% |
| 35Δ | 22.18 | 96.7% | 13.2% | 18.82 | 147.6% | 11.6% |
| 40Δ | 21.64 | 93.6% | 11.0% | 19.42 | 134.4% | 9.2% |
| 45Δ | 21.09 | 90.5% | 8.7% | 20.01 | 121.6% | 6.9% |
| 50Δ | 20.55 | 87.4% | 6.5% | 20.34 | 115.8% | 6.1% |
| 55Δ | 20.00 | 84.3% | 4.3% | 20.66 | 110.1% | 5.3% |
| 60Δ | 19.57 | 88.7% | 3.8% | 20.98 | 104.4% | 4.5% |
| 65Δ | 19.14 | 93.1% | 3.3% | 21.31 | 98.7% | 3.7% |
| 70Δ | 18.72 | 97.5% | 2.8% | 21.63 | 92.9% | 2.9% |
| 75Δ | 18.29 | 101.8% | 2.3% | 21.96 | 87.2% | 2.1% |
| 80Δ | 17.86 | 106.2% | 1.8% | 22.28 | 81.5% | 1.4% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 14.67
- IV
- 415.4%
- B/E move
- 35.6%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 17.62
- IV
- 173.8%
- B/E move
- 16.5%
30Δ
- Pseudo strike
- 22.73
- IV
- 99.7%
- B/E move
- 15.5%
- Pseudo strike
- 18.22
- IV
- 160.7%
- B/E move
- 14.0%
35Δ
- Pseudo strike
- 22.18
- IV
- 96.7%
- B/E move
- 13.2%
- Pseudo strike
- 18.82
- IV
- 147.6%
- B/E move
- 11.6%
40Δ
- Pseudo strike
- 21.64
- IV
- 93.6%
- B/E move
- 11.0%
- Pseudo strike
- 19.42
- IV
- 134.4%
- B/E move
- 9.2%
45Δ
- Pseudo strike
- 21.09
- IV
- 90.5%
- B/E move
- 8.7%
- Pseudo strike
- 20.01
- IV
- 121.6%
- B/E move
- 6.9%
50Δ
- Pseudo strike
- 20.55
- IV
- 87.4%
- B/E move
- 6.5%
- Pseudo strike
- 20.34
- IV
- 115.8%
- B/E move
- 6.1%
55Δ
- Pseudo strike
- 20.00
- IV
- 84.3%
- B/E move
- 4.3%
- Pseudo strike
- 20.66
- IV
- 110.1%
- B/E move
- 5.3%
60Δ
- Pseudo strike
- 19.57
- IV
- 88.7%
- B/E move
- 3.8%
- Pseudo strike
- 20.98
- IV
- 104.4%
- B/E move
- 4.5%
65Δ
- Pseudo strike
- 19.14
- IV
- 93.1%
- B/E move
- 3.3%
- Pseudo strike
- 21.31
- IV
- 98.7%
- B/E move
- 3.7%
70Δ
- Pseudo strike
- 18.72
- IV
- 97.5%
- B/E move
- 2.8%
- Pseudo strike
- 21.63
- IV
- 92.9%
- B/E move
- 2.9%
75Δ
- Pseudo strike
- 18.29
- IV
- 101.8%
- B/E move
- 2.3%
- Pseudo strike
- 21.96
- IV
- 87.2%
- B/E move
- 2.1%
80Δ
- Pseudo strike
- 17.86
- IV
- 106.2%
- B/E move
- 1.8%
- Pseudo strike
- 22.28
- IV
- 81.5%
- B/E move
- 1.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 88.80% | |
| 84.67% | |
| 90.13% | |
| 94.25% | |
| 101.84% | |
| 105.26% | |
| 98.47% | |
| 98.19% | |
| 103.45% | |
| 104.70% |
Biotechnology
NAUT
Nautilus Biotechnology, Inc., a development-stage life sciences company, is dedicated to creating platform technology to quantify and unlock proteome complexity. The company is…
More →NBTX
Nanobiotix SA, a clinical-stage biotechnology, is focused on the development of candidate products for the treatment of cancer. The company is headquartered in Paris, France.
More →NGNE
Description unavailable
More →NKTR
Description unavailable
More →NKTX
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer. The company is headquartered in South San Francisco,…
More →NMRA
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and…
More →